脐带间充质干细胞联合利妥昔单抗治疗系统性红斑狼疮的临床疗效及护理体会  

Clinical Efficacy of UC-MSC Combined with Rituximab in Treating Systemic Lupus Erythematosus and Nursing Experience

作　　者：谭慧莉[1] 

机构地区：[1]中国医科大学附属盛京医院专家门诊,辽宁沈阳110004

出　　处：《中国药业》2015年第9期80-82,共3页China Pharmaceuticals

摘　　要：目的探讨脐带间充质干细胞联合利妥昔单抗治疗系统性红斑狼疮的临床疗效并总结护理体会。方法选择2013年1月至2014年7月医院诊治的30例系统性红斑狼疮患者,随机分为对照组和观察组,各15例。对照组采用脐带血间充质干细胞输注治疗,观察组采用脐带间充质干细胞联合利妥昔单抗治疗,两组患者均给予适当的护理措施。结果治疗后3周及6个月,两组患者系统性红斑狼疮疾病活动度评分(SLEDAI评分)均较治疗前显著降低(P<0.05),且治疗后6个月较治疗后3周下降更明显(P<0.05),但组间治疗后同时点差异无统计学意义(P>0.05);两组患者干扰素γ(IFN-γ)及白细胞介素-4(IL-4)水平均较治疗前显著下降(P<0.05),且观察组下降更明显(P<0.05)。两组患者IL-6、IL-8及IL-10水平较治疗前均显著下降(P<0.05),且同组患者治疗后6个月较治疗后3周下降更明显(P>0.05),但组间差异无统计学意义(P>0.05)。两组患者治疗后不良反应发生率比较,差异无统计学意义(P>0.05)。结论脐带间充质干细胞联合利妥昔单抗治疗系统性红斑狼疮,具有靶向作用且安全性良好,能有效清除病理性B细胞且减少炎症因子的释放,有效改善机体免疫性炎症的状态。对患者的精心护理也是治疗成功的关键。Objective To explore the clinical effect of umbilical cord mesenchymal stem cells （ UC-MSC ） combined with rituximab in the treatment of systemic lupus erythematosus （ SLE ） and to summarize the nursing experience. Methods 30 cases of SLE in our hospi-tal from January 2013 to July 2014 were selected and randomly divided into the control group and the observation group, 15 cases in each group. The control group adopted the therapy of UC-MSC infusion, while the observation group was given the therapy of UC-MSC combined with rituximab. The two groups were given the appropriate nursing measures. Results The SLE disease activity index （ SLEDAI ） scores after 3-week and 6-month treatment in the two groups were significantly decreased compared with before treatment （ P 〈 0. 05 ） , moreover the decrease after 6-month treatment was more obvious than that after 3-week treatment （ P 〈 0. 05 ） , but the difference at the same time point between the two groups had no statistical significance （ P 〉 0. 05 ）;the IFN-gamma and IL-4 levels after treatment were significantly decreased compared with before treatment （ P 〈 0. 05 ） , moreover the decrease in the observation group was more significant （ P 〈 0. 05 ） . The IL-6, IL-8 and IL-10 levels after treatment were significantly decreased compared with before treatment （ P 〈 0. 05 ） , moreover the decrease after 6-month treatment in the same group was more significant than that after 3-week, but the difference between the two group had no statistical significance （ P 〉 0. 05 ） . The occurrence rate of adverse reactions after treat-ment had no statistical difference between the two groups （ P 〉 0. 05 ） . Conclusion UC-MSC combined with rituximab for treating SLE has the targeted effect and good safety, can effectively eliminate pathological B cells, reduce the release of inflammatory cytokines and improve the body ’ s immune inflammation status. The meticulous nursing on patients is also a key for successful treatment.

关 键 词：脐带间充质干细胞 利妥昔单抗 系统性红斑狼疮 临床疗效 护理 

分 类 号：R969.4[医药卫生—药理学] R977.6[医药卫生—药学]